Expert Interview
Discussing the FDA expanded label for ENTYVIO® (vedolizumab) for subcutaneous (SC) administration maintenance therapy in adults with moderately to severely active Crohn’s Disease.
Ticker(s): TAKInstitution: UI Health
- Manages approximately 50 patients with HBV
- Area of focus is in inflammatory bowel diseases (IBD), including Crohn's disease and colitis
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
